Analysed ERNEXA THERAPEUTICS INC (ERNA:NASDAQ) News Sources
Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
31-03-2026
yahoo.com
Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models
06-05-2026
yahoo.com
Ernexa Therapeutics (ERNA) Preclinical Data Shows 100% Survival and Complete Tumor Clearance in Ovarian Cancer Models
06-05-2026
advfn.com
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101
11-05-2026
yahoo.com
Trump Rattled Markets Again and These 3 Forgotten Stocks Under $30 Were the Unlikely Winners
18-05-2026
247wallst.com
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity
20-05-2026
yahoo.com
Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development
27-05-2026
yahoo.com
What is the current price of ERNEXA THERAPEUTICS INC (ERNA:NASDAQ)?
The current price of ERNEXA THERAPEUTICS INC (ERNA:NASDAQ) is $6.16.
ERNEXA THERAPEUTICS INC (ERNA:NASDAQ) absolute price change since previous trading day?
The absolute price change of ERNEXA THERAPEUTICS INC (ERNA:NASDAQ) since the previous trading day is $-0.395.
ERNEXA THERAPEUTICS INC (ERNA:NASDAQ) percentage price change since previous trading day?
The percentage price change of ERNEXA THERAPEUTICS INC (ERNA:NASDAQ) since the previous trading day is -6.0259%.
What is the most recent average sentiment score for ERNEXA THERAPEUTICS INC (ERNA:NASDAQ)?
The most recent average sentiment score for ERNEXA THERAPEUTICS INC (ERNA:NASDAQ) is 75 out of 100.
What is the most recent average sentiment for ERNEXA THERAPEUTICS INC (ERNA:NASDAQ)?
The most recent sentiment for ERNEXA THERAPEUTICS INC (ERNA:NASDAQ) is .
SEC-8K** Filing Available For ERNEXA THERAPEUTICS INC (ERNA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.